U.S. health regulators have ordered drugmakers to conduct clinical trials involving a total of 53,000 patients to test the safety of a controversial class of inhaled asthma drugs that are already on the market.
The trials are being required to demonstrate the safety of medicines known as long-acting beta-agonists (LABAs) when used in combination with inhaled steroids, another class of asthma drugs, the U.S. Food and Drug Administration said on Friday.
LABAs to be studied are AstraZeneca's Symbicort, GlaxoSmithKline's Advair Diskus, Merck & Co's Dulera, and Novartis AG's Foradil.
--
******************************************************
For Health Information you can use, Follow, Connect, Like us on (Most Invites Accepted):
http://www.nursefriendly.com/social/
Twitter!
http://www.nursefriendly.com/twitter
Facebook:
http://www.nursefriendly.com/facebook
What's New:
http://www.nursefriendly.com/new/
Blogger:
http://4nursing.blogspot.com/
Linked In:
http://www.linkedin.com/in/nursefriendly
Nursing Entrepreneurs, Nurses In Business
http://nursingentrepreneurs.ning.com/
StumbleUpon,
http://www.nursefriendly.com/stumbleupon
******************************************************
Sincerely,
Andrew Lopez, RN
Nursefriendly, Inc. A New Jersey Corporation.
38 Tattersall Drive, Mantua New Jersey 08051
http://www.nursefriendly.com info@nursefriendly.com ICQ #6116137
856-415-9617, (fax) 415-9618
150,000 + Nurse-Reviewed & Approved Nursing Links
http://www.4nursing.com
http://www.legalnursingconsultant.com
http://www.nursinghumor.com
http://www.nursefriendly.com
http://www.nursingcasestudy.com
http://www.nursingentrepreneurs.com
http://www.nursingexperts.com
